Analyzing Paradigm Medical Industries (OTCMKTS:PDMI) and IceCure Medical (NASDAQ:ICCM)

IceCure Medical (NASDAQ:ICCM) and Paradigm Medical Industries (OTCMKTS:PDMI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IceCure Medical and Paradigm Medical Industries, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	0	0	1	1	3.50
Paradigm Medical Industries	0	0	0	0	0.00

IceCure Medical presently has a consensus target price of $2.50, indicating a potential upside of 100.00%. Given IceCure Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe IceCure Medical is more favorable than Paradigm Medical Industries.

Volatility and Risk

IceCure Medical has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Paradigm Medical Industries has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500.

Institutional and Insider Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 11.1% of Paradigm Medical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares IceCure Medical and Paradigm Medical Industries”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.67 million	18.90	-$14.65 million	($0.29)	-4.31
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A

Paradigm Medical Industries has lower revenue, but higher earnings than IceCure Medical.

Profitability

This table compares IceCure Medical and Paradigm Medical Industries’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-376.85%	-124.44%	-87.70%
Paradigm Medical Industries	N/A	N/A	N/A

Summary

IceCure Medical beats Paradigm Medical Industries on 7 of the 11 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.